Diabetes Clinical Trials in San Francisco

Showing 361-380 of 453 trials

Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans

NCT01681693

The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. The investigators will study individuals with particular genotypes of the human organic cation transporter, (hOCT3), and the multidrug and toxin extrusion transporter, MATE1 to test the hypothesis that genetic variation in hOCT3 and hMATE1 are associated with variation in the pharmacokinetics and/or pharmacodynamics of the antidiabetic agent, metformin.

HealthyType 2 Diabetes Mellitus

University of California, San Francisco33 participantsStarted Feb 2010

San Francisco, California, United States

COMPLETEDNA< 1 mile

Study of Medical Assistant Health Coaching in Primary Care for Patients With Chronic Conditions

NCT01220336

Randomized control trial studying the effect of medical assistant health coaching for patients with diabetes, hypertension and hyperlipidemia within two San Francisco primary care community clinics, Mission Neighborhood Health Center and Southeast Health Center

DiabetesHypertensionHyperlipidemia

University of California, San Francisco441 participantsStarted Apr 2011

San Francisco, California, United States • San Francisco, California, United States

COMPLETEDPhase 38.4 miles

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

NCT00968708

The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.

Diabetes Mellitus, Type 2Acute Coronary Syndrome

Takeda5,380 participantsStarted Sep 2009

Birmingham, Alabama, United States • Dothan, Alabama, United States • Mobile, Alabama, United States +905 more locations

Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans

Study of Medical Assistant Health Coaching in Primary Care for Patients With Chronic Conditions

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

Diabetes Trials in Other Cities

Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

Dapagliflozin DPPIV Inhibitor add-on Study

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions

Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies

The CareFUL Prevention Trial

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler

Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

Other Conditions in San Francisco